Osimertinib (AZD9291)

For research use only. Not for use in humans.

製品コードS7297

CAS No. 1421373-65-0

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

サイズ

価格(税別)

在庫

5mg	JPY 18100	あり
10mg	JPY 24400	あり
100mg	JPY 118200	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(205)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明

特性

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

ターゲット

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

体外試験

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. ^[2]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC-9/BRc1	Mkn1SpVv[3Srb36gRZN{[Xl?	NGjhVGY2OCCwTR?=	NHjwUmszPCCq	M3HaWWROW09?	MmfzbY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	M33adFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|I2Lz5{NUS3O\|MzPTxxYU6=
PC-9/ERc1	M1LRWGZ2dmO2aX;uJGF{e2G7	NIX1PGM2OCCwTR?=	M1T2[lI1KGh?	NXP4PFBPTE2VTx?=	MULpcoR2[2W\|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
VP-2	NYS1RllXTnWwY4Tpc44hSXO\|YYm=	MUK1NEBvVQ>?	NUSwVVVkOjRiaB?=	MUfEUXNQ	MmTabY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	NWXneVg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/BRc1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLQOVAhdk1?	MmDYNVAh\A>?	MXzEUXNQ	NF71ZYRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC-9/ERc1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fubVUxKG6P	NFmyZo8yOCCm	M362O2ROW09?	MVvpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHzvcocufGW{bTCoNVAu\GG7KTDndo94fGhiaX7obYJqfGmxbjDhd5NigXN?	MojEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
VP-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEX6cIU2OCCwTR?=	MUixNEBl	NHvCTnNFVVOR	NH;a[HdqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO=	NYDaWY5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC9 GR4	NGfhfG1HfW6ldHnvckBCe3OjeR?=	MnPJNE0yOCEQvF2=	M4fJ[VczKGh?		NIPIR3NqdmirYnn0d:KhTUeIUjDwbI9{eGixconsZZRqd25iYX7kJIRwf26\|dILlZY0he2mpbnHsbY5oyqB?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2OE[zN{c,OjV7NEi2N\|M9N2F-
PC9	M2DubGZ2dmO2aX;uJGF{e2G7	NYHwNo45OC1zMDFOwG0>	NXjn[XJJPzJiaB?=		MUTpcohq[mm2czDXWEBGT0[UIHH0JIxwfyClb37j[Y51emG2aX;udy=>	M3fZcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 GR4	NVn0c4hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmezNE0yOCEQvF2=	NH7Fcms4OiCq		NFP2[2JqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	NUHUOlQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFg3OzNpPkK1PVQ5PjN\|PD;hQi=>
BAF3	NX3PXJRsTnWwY4Tpc44h[XO\|YYm=		NUXkNXVxPzJiaB?=		MVHHTVUxKD1iMD6wNFA{KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	MYLGeY5kfGmxbjDhd5NigQ>?		M3PnclczKGh?		MXnHTVUxKD1iMD6wNFA{KM7:TR?=	NFH6U3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	Ml3lSpVv[3Srb36gZZN{[Xl?		M1HnVVczKGh?		NYG1PHo4T0l3MDC9JFAvODBzIN88US=>	M3TkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	MojCSpVv[3Srb36gZZN{[Xl?		NW\zRmVVPzJiaB?=		M{S5[mdKPTBiPTCwMlAxOSEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9	NVTMcpNQTnWwY4Tpc44h[XO\|YYm=		NYXsVmxsPzJiaB?=		NIj0fmhIUTVyIE2gNE4xODJizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	NYjtR4NRTnWwY4Tpc44h[XO\|YYm=		MUK0JIg>		NU\zZXVKTUN3MDC9JFAvODB{IN88US=>	NFXhUFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	M2DTXWZ2dmO2aX;uJIF{e2G7		MonvN{Bp		MkXxTWM2OCB;IECuNFAzPSEQvF2=	NEexclM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
H1975	MYXGeY5kfGmxbjDhd5NigQ>?		M4H2NlMhcA>?		NHfyXndKSzVyIE2gNE4xODJ3IN88US=>	NHzm[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
H3255	M{j5Z2Z2dmO2aX;uJIF{e2G7		M1TOT\|MhcA>?		NILUdpJKSzVyIE2gNE4xODRzIN88US=>	NH3uelA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
NCI-H1975	NUPDZ\|Q3TnWwY4Tpc44h[XO\|YYm=		MV63NkBp		NG\wPHVIUTVyIE2gNE4xODVizszN	NGS3bIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9	NET1eldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NFr0bWQ4OiCq		Mo\ETWM2OCB;IECuNFA3PSEQvF2=	NWT1U4NIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
NCI-H1975	MkH5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MoXGO\|IhcA>?		MVLJR\|UxKD1iMD6wNVA2KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
Sf21	MVfGeY5kfGmxbjDhd5NigQ>?				MX;JR\|UxKD1iMD6wNVIh\|ryP	NHy4Wm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
PC9-DRH	NI\DTlNHfW6ldHnvckBie3OjeR?=		NXzpVIt5OiCq		MmXNTWM2OCB;IECuNFE{KM7:TR?=	NEXMOZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
BAF3	M1vsXmZ2dmO2aX;uJIF{e2G7		M2rFblczKGh?		M4G2WmdKPTBiPTCwMlAyOyEQvF2=	NEHQb249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	M4rWWmZ2dmO2aX;uJIF{e2G7		NGqwW5k6PiCq		NGfU[plGSzVyIE2gNE4xOTRizszN	NX;MWpp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlUzPjlpPkK4NlI2OjZ7PD;hQi=>
HCC827	NFvJZWNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		Mk\QPVYhcA>?		MkTBSWM2OCB;IECuNFE1KM7:TR?=	NIjTeYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	NGq1WmxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MVi5OkBp		MWLFR\|UxKD1iMD6wNVQh\|ryP	M1n4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
NCI-H1975	MVnGeY5kfGmxbjDhd5NigQ>?		NXOwSVVWOiCq		MkXjTWM2OCB;IECuNFE2KM7:TR?=	MoTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
H1975	M{DHV2Z2dmO2aX;uJIF{e2G7		NWPBdIQ3OiCq		M3;1SGlEPTBiPTCwMlAyPSEQvF2=	NH\ScXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2PFI2Oyd-Mk[5OlgzPTN:L3G+
PC9	NX\vTnhDTnWwY4Tpc44h[XO\|YYm=		NFPGeoEzKGh?		M{\5eGlEPTBiPTCwMlAyPyEQvF2=	NFrwOZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2PFI2Oyd-Mk[5OlgzPTN:L3G+
NCI-H1975	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NXjiPHJNPzJiaB?=		NXvROXZmUUN3MDC9JFAvODF7IN88US=>	MnjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
NCI-H1975	M3;JN2Z2dmO2aX;uJIF{e2G7		NVv1O\|NGQTZiaB?=		NVy4SpJsTUN3MDC9JFAvODF7IN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
NCI-H1975	NGnIU3hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NVzQW4c6QTZiaB?=		NHvl[nFGSzVyIE2gNE4xOTlizszN	NHLpPG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wN\|k6OSd-Mki2NFM6QTF:L3G+
NCI-H1975	NHnzNIZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1jQOFczKGh?		M2Lmd2lEPTBiPTCwMlAyQSEQvF2=	Mmn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN\|QxRC:jPh?=
HCC827	M3HUXGZ2dmO2aX;uJIF{e2G7		MkC4NkBp		M2Hr[mlEPTBiPTCwMlAzOyEQvF2=	NYPCVGNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
NCI-H1975	M2LYPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NWq5R\|JoPzJiaB?=		NF3ndXZKSzVyIE2gNE4xOjNizszN	NIm5SVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
PC9	MW\DfZRwfG:6aXPpeJkh[XO\|YYm=		MXO3NkBp		M3v4XmdKPTBiPTCwMlAzOyEQvF2=	M{frOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975	NGHpcZlEgXSxdH;4bYNqfHliYYPzZZk>		NVz4boFuPzJiaB?=		NHrS[o5IUTVyIE2gNE4xOjRizszN	MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
HCC827	MljqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M{fVclczKGh?		NHXBWohKSzVyIE2gNE4xOjV2IN88US=>	NV3Fe4VtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
HCC827	NGXjbJdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M{jvR\|czKGh?		NFfsTWNKSzVyIE2gNE4xOjdizszN	NVjPSmNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd\|PD;hQi=>
HCC827	NY[wUWVqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M1TJcVczKGh?		NVfkWpVCUUN3MDC9JFAvODJ5IN88US=>	NXHhSIhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
NCI-H1975	Mnf5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MYO3NkBp		M4LRW2lEPTBiPTCwMlA{KM7:TR?=	M164eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN\|U4QTxxYU6=
H3255	NWn5OldRTnWwY4Tpc44h[XO\|YYm=		NWj2bJhjPzJiaB?=		NVj6RZNET0l3MDC9JFAvODN\|IN88US=>	NE\NZ\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
H3255	M3HFRWZ2dmO2aX;uJIF{e2G7		NX:yVZp7OiCq		MWPJR\|UxKD1iMD6wN\|Yh\|ryP	Ml;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
NCI-H1975	MlTYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M1LFbVczKGh?		NXvjVZk2UUN3MDC9JFAvODRzIN88US=>	NFG0RlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N\|AyQTJ:L3G+
NCI-H1975	Mlr1SpVv[3Srb36gZZN{[Xl?		M1\LeFEhcA>?		MXPJR\|UxKD1iMD6wOFEh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmyOkc,Ojl3M{S5NlY9N2F-
BAF3	M1HzSWZ2dmO2aX;uJIF{e2G7		MnTROEBp		M2PXemVEPTBiPTCwMlA1OyEQvF2=	M17FblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	MlHkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M1HlPFczKGh?		MX3JR\|UxKD1iMD6wOFczKM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV5NkK3Nkc,Ojl3N{[yO\|I9N2F-
NCI-H1975	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MXG3NkBp		NY\HVJdyUUN3MDC9JFAvODV{IN88US=>	NYL0S5VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|E3OzlpPkK3NVMyPjN7PD;hQi=>
PC9	M4TsOWZ2dmO2aX;uJIF{e2G7		NYHGXHhHOiCq		NHjE[ZFKSzVyIE2gNE4xPTZizszN	NYLHSmJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
NCI-H1975	NXzPWo03S3m2b4TvfIlkcXS7IHHzd4F6		Mn3nO\|IhcA>?		M4PaZWlEPTBiPTCwMlA3KM7:TR?=	NVzMfZFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV\|PD;hQi=>
HCC827	NX30SpZFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=				M{DZeGlEPTBiPTCwMlA3OTZizszN	NX3ZOXlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
NCI-H1975	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?				MYXJR\|UxKD1iMD6wOlch\|ryP	MoH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
HaCaT	MXXGeY5kfGmxbjDhd5NigQ>?		MVSzJIg>		MUnJR\|UxKD1iMD6wO\|M4KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
NCI-H1975	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NH3VOoY4OiCq		NYDJeVFKUUN3MDC9JFAvOTNizszN	NHrO[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
A431	MVHGeY5kfGmxbjDhd5NigQ>?		NHrYW4QyKGh?		NW\CUXppUUN3MDC9JFAvOTRzIN88US=>	NI\GTIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
A549	MXfGeY5kfGmxbjDhd5NigQ>?				NWPCOZB4UUN3MDC9JFAvOTVizszN	NXPYdoRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
Calu3	NFfB[GFEgXSxdH;4bYNqfHliYYPzZZk>		MWK3NkBp		NIHje\|VIUTVyIE2gNE4zPjRizszN	NYTlU3hMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
Sf9	NHLTNm9HfW6ldHnvckBie3OjeR?=		NU\OUJl[OjBibXnudy=>		NUT6V5ZtUUN3MDC9JFAvOjd6IN88US=>	NUH4XnJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PFIyPTFpPkK4OFgzOTVzPD;hQi=>
BAF3	NUXrdZFRTnWwY4Tpc44h[XO\|YYm=		NHvhdnA4OiCq		NVn5UZlwT0l3MDC9JFAvOyEQvF2=	NXLw[3pFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	MYnGeY5kfGmxbjDhd5NigQ>?		M{XpbFczKGh?		MVLHTVUxKD1iMD6zNUDPxE1?	NVLnZ5AxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H460	M{H6R2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M4PhWFczKGh?		M3\ZRWlEPTBiPTCwMlQyPTlizszN	NX3P[Y5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
LoVo	NX7JW29qTnWwY4Tpc44h[XO\|YYm=		NVLLdIY6OiCq		MkL4TWM2OCB;IECuOFgh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo	MYLGeY5kfGmxbjDhd5NigQ>?		NVOxR\|hsOiCq		MmfOTWM2OCB;IECuOFgh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NkK2O{c,Ojd7OU[yOlc9N2F-
A549	NVLvdWlTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MWe3NkBp		NEfSNJBKSzVyIE2gNE41QDZizszN	M3rRT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3	NF;EfopHfW6ldHnvckBie3OjeR?=		MljDO\|IhcA>?		NVjLc2FJT0l3MDC9JFAvPSEQvF2=	NY\5[3R1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A549	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MX23NkBp		MUDJR\|UxKD1iMD61N{DPxE1?	MoqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
A549	M1fBR2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NE\LTpM4OiCq		NG\KOI1KSzVyIE2gNE42OyEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
BAF3	Ml;xSpVv[3Srb36gZZN{[Xl?		Mm\nO\|IhcA>?		MmK0S2k2OCB;IECuOVUh\|ryP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	M1Wz[GZ2dmO2aX;uJIF{e2G7		NIrFOo04OiCq		NYPG[GJsT0l3MDC9JFAvPTZizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HEK293	MoDnSpVv[3Srb36gZZN{[Xl?				M{faRmlEPTBiPTCwMlU4KM7:TR?=	NHfSSpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
BAF3	M4TWdWZ2dmO2aX;uJIF{e2G7		M{LNdFczKGh?		MnjTS2k2OCB;IECuOVkh\|ryP	NXX0b\|I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A431	MkXrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				MlfPTWM2OCB;IECuOlE2PiEQvF2=	NIG1d2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
HT-29	MYnDfZRwfG:6aXPpeJkh[XO\|YYm=		NGPufIU4OiCq		MlrVTWM2OCB;IECuOlUh\|ryP	MkPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
A431	NVfMeGRNTnWwY4Tpc44h[XO\|YYm=		NUXFSHBJQTZiaB?=		NVTLcZN4TUN3MDC9JFAvPjZ5IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
A431	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NUHXWIdwQTZiaB?=		MXjFR\|UxKD1iMD62O{DPxE1?	NGHTWWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
A431	NUTWZmJCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NWro[pE1PzJiaB?=		MnjHTWM2OCB;IECuOlg2KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmyOkc,Ojl3M{S5NlY9N2F-
A431	M4f1VWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWq5OkBp		MXfFR\|UxKD1iMD63JO69VQ>?	NFj2blQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wN\|k6OSd-Mki2NFM6QTF:L3G+
A549	M{LNXmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{XXVVczKGh?		NYfiRZJbUUN3MDC9JFAvQDdizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
A431	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MUC3NkBp		MXfJR\|UxKD1iMD64PVMh\|ryP	M13aclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxOlM6Lz5{N{GzNVY{QTxxYU6=
BA/F3	NHzvbFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NUPmVY9TPzJiaB?=		NYO3c\|RwUUN3MDC9JFEh\|ryP	M3vwdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BAF3	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoG5O\|IhcA>?		M13PXWdKPTBiPTCxMlIh\|ryP	M1nYfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H2122	Mlz2SpVv[3Srb36gZZN{[Xl?		NG\DcHY4OiCq		MXjHTVUxKD1iMT6yJO69VQ>?	M2XIUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A431	M1n1S2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M4[xVVczKGh?		M12yPWlEPTBiPTCxMlI1KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431	NEHFTpBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NXzHfoZ6PzJiaB?=		MX\JR\|UxKD1iMT6yOkDPxE1?	NGDrUXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N\|AyQTJ:L3G+
A431	M4L5UmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MnL5O\|IhcA>?		NUXNVoZtUUN3MDC9JFEvPjB2IN88US=>	M37TXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN\|U4QTxxYU6=
A549	NEj0SZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MnnkPVYhcA>?		MkTDSWM2OCB;IEGuPFMh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
CHL	NYLOUGxVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{P2SVczKGh?		NH\aTplIUTVyIE2gNk46KM7:TR?=	M1nJcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H1355	M2TnNmZ2dmO2aX;uJIF{e2G7		M1:xPVczKGh?		NEDt[ZdIUTVyIE2gN{DPxE1?	MofnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1703	M1TX[WZ2dmO2aX;uJIF{e2G7		NHuwPFM4OiCq		M1q2T2dKPTBiPTCzMlUh\|ryP	Ml3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A549	NGGxOZBHfW6ldHnvckBie3OjeR?=		NHrUWlk4OiCq		NYOxSHpUT0l3MDC9JFMvPSEQvF2=	M{L4[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
CHO	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml7lO\|IhcA>?		NYnSVIVnT0l3MDC9JFQvOiEQvF2=	NIf3e409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NWDxeGFVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NEHFRYE4OiCq		NWjETFBGUUN3MDC9JFQvPjFizszN	M37SXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
BAF3	Mo\JRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NYH3Roc5PzJiaB?=		MW\JR\|UxKD1iNT6xOUDPxE1?	MofRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BEAS2B	NHnsVWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		Mnf4O\|IhcA>?		NXv1ZYpMUUN3MDC9JFE1NjlizszN	Mnz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MU[2OFEoRjJ6N{G2OlQyRC:jPh?=
NCI-H1975	NUDXc\|R6TnWwY4Tpc44h[XO\|YYm=		MXiyJIg>		MWDJR\|UxKD1iMUWg{txO	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
PC9	NUTISFFCTnWwY4Tpc44h[XO\|YYm=		MkLKNkBp		MWXJR\|UxKD1iMUeg{txO	NYXNO5FzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
LoVo	MV7GeY5kfGmxbjDhd5NigQ>?		NYHMW5ljOiCq		NWHYPYVHUUN3MDC9JFQ5OCEQvF2=	M{e1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975	NHLDflBCdnSrdIXtc5Ih[WO2aY\peJkh[XO\|YYm=				M1j1dmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOi53IH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s	MlT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
rat hepatocytes	MnLnSpVv[3Srb36gZZN{[Xl?				NEXE[FlKdnS{aX7zbYMh[2ynYYLhcoNmKGmwIILheEBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=>	NFzUe5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
human hepatocytes	M{fs[WZ2dmO2aX;uJIF{e2G7				MV\JcpRzcW6\|aXOgZ4xm[XKjbnPlJIlvKGi3bXHuJIhmeGG2b3P5eIV{KG2nYYP1doVlKHCncjCxNEc3KGOnbHzz	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	MnzsRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				MVXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEm3NG0h\G:3YnzlJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	M336b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975	MoLKSpVv[3Srb36gZZN{[Xl?				NH;x[JpU\WynY4Tpeol1gSCrbnTlfEwhemG2aX:gc4YhUUN3MDDmc5IhTUeIUjDUO\|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHSxIFnDOVAh\m:{IIfpcIQhfHmyZTDFS2ZTKGW6cILld5NqdmdiaIXtZY4hSTR\|MTDj[Yxtew>?	NXnSVWx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|AyQTJpPkK5O\|MxOTl{PD;hQi=>
NCI-H1975	MU\BcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				NVWxb5V4SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhTUeIUjDUO\|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHinbn;ndoFnfGWmIHnuJGJCVEJxYzDheIh6dWmlIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOTBibXevb4ctKHCxIHLp[EBnd3JiMkGg[IF6ew>?	NHS2W4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N\|AyQTJ:L3G+
HCC827	NInEW5RCeG:ydH;zbZMh[XO\|YYm=				MYjJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCHN{S2MWE4PTBiZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IHXhdox6KGGyb4D0c5Rq[yClZXzsd{BifCB\|IIXNJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[tSmlVSy:ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7IDjSeoIhRSBzLkO0KUk>	Mn7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
HCC827	MnT6RZBweHSxc3nzJIF{e2G7				NEDUXmtKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIxifGViYYDvdJRwfGmlIHPlcIx{KGG2IEOgeW0h[W[2ZYKgNlQhcHK\|IHL5JGFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comgLHJ3[iB;IEK3MlE1LSl?	NFXmWFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
A549	NXfFUWttTnWwY4Tpc44h[XO\|YYm=				M2LBXXNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKGi3bXHuJGE2PDliY3XscJMh\XiycnXzd4lv\yC5aXzkMZR6eGViRVfGVk9MNVKjczDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCmb4XicIUhdXW2YX70	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
HCC827	MoHYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M3z1SlczKGh?		NHrqT2JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|gzPyClZXzsd{BifCBzIIXNJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MmX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO\|IoRjJ7NUe2NlczRC:jPh?=
BAF3	MlTlSpVv[3Srb36gZZN{[Xl?		NWjVTXdIOiCq		MoXxTY5pcWKrdHnvckBw\iCHR1\SJHQ4QTCPL1y4OVhTN0N5OUfTJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDFS2YucW6mdXPl[EBz\WOncITvdkBxcG:\|cHjvdplt[XSrb36gZZQhOSC2bzCzJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhTUeIIIP0bY12dGG2aX;uJIZweiBzNTDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
BAF3	MnfQSpVv[3Srb36gZZN{[Xl?		NG\yTIMzKGh?		Mn;aTY5pcWKrdHnvckBw\iCHR1\SJFE6TC:WN{mwUU9EPzl5UzDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRVfGMYlv\HWlZXSgdoVk\XC2b4KgdIhwe3Cqb4L5cIF1cW:wIHH0JFEhfG9iMzD1UUBxemWrbnP1ZoF1\WRiZn;yJFIhcHK\|IH\vcIxwf2WmIHL5JGVITiC\|dHnteYxifGmxbjDmc5IhOTVibXnud{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M17j[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
NCI-H1975	M4LWbmFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				NH\qVY9CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNieHXuc4dz[W[2ZXSgbY4hW1SRQ1utSo95djGwdT;ObpUhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3bX;yJIdzd3e2aDDheEAzOCCvZz;r[{9l[XluIIDvJJFlKG[xcjCxOEBl[Xm\|IILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s	Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|OUWyNVkoRjJ6M{m1NlE6RC:jPh?=
Caco2	NUm1VHlMTnWwY4Tpc44h[XO\|YYm=		NVvYfoJbOiCq		NVrGTFViTW[obIX4JJJifGmxIH;mJIFxeGG{ZX70JJBmem2nYXLpcIl1gSCocn;tJIJie2:uYYTldoFtKHOrZHWgeI8h[XCrY3HsJJNq\GVib4\ldkBieGmlYXygd4ll\SC2bzDiZZNwdGG2ZYLhcEB{cWSnIH;2[ZIhcW5iaIXtZY4hS2Glb{KgZ4VtdHNiYYSgOUB2VSCrbnP1ZoF1\WRiZn;yJFIhcHK\|	NUG4Z5BoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
A431	MUXGeY5kfGmxbjDhd5NigQ>?				M3rqO3NmdGWldHn2bZR6KHKjdHnvJI9nKEWFNUCg[o9zKGi3bXHuJGE1OzFiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRVfGVkB1dyCHQ{WwJIZweiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJvTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfA>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
Caco2	NEjP[WhHfW6ldHnvckBie3OjeR?=		MV:yJIg>		MofvRZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{BieGmlYXygeI8h[mG\|b3zheIVz[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN?	M{O4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
Caco2	MVXGeY5kfGmxbjDhd5NigQ>?		M{fqflIhcA>?		MVjBdJBiemWwdDDw[ZJu\WGkaXzpeJkh[WO{b4PzJIJie2:uYYTldoFtKHSxIHHwbYNidCC\|aXTlJIlvKGi3bXHuJGNi[29{IHPlcIx{KGG2IEWgeW0hcW6ldXLheIVlKG[xcjCyJIhzew>?	M2XrVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
NCI-H1975	MnPrSpVv[3Srb36gZZN{[Xl?		NHfIfIs1KGh?		M1LFeWlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQhcW5iaIXtZY4hVkOLLVixPVc2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	M3;2dmZ2dmO2aX;uJIF{e2G7		NEnMZnA1KGh?		NXm3eXoyUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIlvKGi3bXHuJGhESzh{NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSWu2IIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhxU3XyOFc{KHOrdHWgZZQhOSC3TTDt[YF{fXKnZDDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NXO0enB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975	NVi1WZp4SXCxcITvd4l{KGG\|c3H5		MYi0PEBp		M3n5WWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	MnLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827	NXnxV4tSSXCxcITvd4l{KGG\|c3H5		Mkf3OFghcA>?		MYDJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9	NEnJbmtCeG:ydH;zbZMh[XO\|YYm=		NWHMRXdFPDhiaB?=		NHvhW2JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	M3zXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255	NGHxZlNCeG:ydH;zbZMh[XO\|YYm=		MlKzOFghcA>?		MoXJTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKM{K1OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4VkBufXSjboSgZZN{\XO\|ZXSgZZMh[2G\|cHHz[U0{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK\|IHL5JIludXWwb3Lsc5R1cW6p	M2Pv[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	NUm4SldwSXCxcITvd4l{KGG\|c3H5		M{\pOFQ5KGh?		M{LXW2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	M{f3e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
PC9	NUHkV2V2SXCxcITvd4l{KGG\|c3H5		MW[0PEBp		Mmm1TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZTDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[y=>	NEnjN3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	MkHURZBweHSxc3nzJIF{e2G7		Mni5OFghcA>?		M1q0Xmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IGDBVnAh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	M3fYd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255	M3nDeGFxd3C2b4Ppd{Bie3OjeR?=		M1\NcFQ5KGh?		NFTlN3JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFizNlU2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	NXKxVo83TnWwY4Tpc44h[XO\|YYm=				NXW2ZmJkW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iQUSzNUBk\WyuczDoZZJjd3Krbnege4lt\C22eYDlJGVITlJ?	NED6WYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
human hepatocytes	MoHGSpVv[3Srb36gZZN{[Xl?				NYfReWZIUW62cnnud4lkKGOuZXHyZY5k\SCrbjDoeY1idiCqZYDheI9kgXSnczDhd5Nme3OnZDDw[ZIhdWmubHnvckBk\Wyucx?=	NF\ZUpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
rat hepatocytes	NY[ydpdFTnWwY4Tpc44h[XO\|YYm=				MYjJcpRzcW6\|aXOgZ4xm[XKjbnPlJIlvKHKjdDDo[ZBifG:leYTld{Bie3Onc4Pl[EBx\XJibXnscIlwdiClZXzsdy=>	MnPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
A549, NCI-H1975	MUfGeY5kfGmxbjDhd5NigQ>?				M{\UeHNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHnuJIh2dWGwIF7DTU1JOTl5NTDj[Yxtew>?	M3zYXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
A549, PC9	MVHGeY5kfGmxbjDhd5NigQ>?				MWDT[Yxm[3Srdnn0fUBz[XSrbzDv[kBKSzVyIH\vdkBGT0Zvc4TpcZVt[XSnZDD3bYxlKHS7cHWgSWdHWiCrbjDoeY1idiCDNUS5JINmdGy\|IITvJGlEPTBiZn;yJGVITlJiZHXs[ZRqd25ibYX0ZY51KGmwIHj1cYFvKFCFOTDj[Yxtew>?	M2fsXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
HCC827	NFHpelNCeG:ydH;zbZMh[XO\|YYm=				M2H5e2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYhfG9iQUe1NEBl\WyndHnvckBufXSjboSgZZN{\XO\|ZXSgZZMh\WG{bImgZZBweHSxdHnjJINmdGy\|IHH0JFMhfU1iYX\0[ZIhOjRiaILzJIJ6KEGwbnX4bY4hXi2ISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkhMFK4YjC9JFEvOzRidH:gNU43PyVr	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
NCI-H1975	NVLINVBlTnWwY4Tpc44h[XO\|YYm=				M2j2SGlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO\|kxVSCmb4XicIUhdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDoeY1idiCQQ1mtTFE6PzViY3XscJMh[XRiMTD0c{AyODBibl2gZpkhX2W\|dHXyckBjdG:2IH3leIhw\A>?	MknyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7ME[xNVQoRjJ7OUC2NVE1RC:jPh?=
A431	Mn60SpVv[3Srb36gZZN{[Xl?				MVPT[Yxm[3Srdnn0fUBz[XSrbzygdoF1cW9iSVO1NEBnd3JiaIXtZY4hSTR\|MTDj[YxteyCxdnXy[ZhxemW\|c3nu[{B4cWymLYT5dIUhTUeIUjD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNM2w5PTiUIH31eIFvfA>?	NID2[IM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVY{QSd-MkexN\|E3Ozl:L3G+
PC9	NEnQUppCdnSrdIXtc5Ih[WO2aY\peJkh[XO\|YYm=				MnH5RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCBzMDDt[{9s\y:mYYmsJJBwKHGmIH\vdkA4KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MoTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
A431	MnjLRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				NWrWc\|JOSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDVibXevb4cw\GG7LDDwc{By\CCob4KgO{Bl[Xm\|IILlcIF1cX[nIITvJINwdnS{b3y=	NHLIRVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	p-EGFR / p-AKT / p-ERK; PubMed: 28416483 Cancer Res PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib. ABCB1; PubMed: 27649127 Molecules The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.	28416483 27649127
Growth inhibition assay	Cell viability; PubMed: 31043587 Cell Death Dis Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. P < 0.05, P < 0.01, **P < 0.005 by t-test.	31043587
Immunofluorescence	Ki67 / γH2AX / p16; PubMed: 29212784 EMBO Mol Med PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. P ≤ 0.01, *P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.	29212784

体内試験

AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. ^[2]

お薦めの試験操作（参考用のみ）

動物試験： ^[2]	- 合併動物モデル： Mice bearing PC9 and H1975 xenograft tumors 投薬量： ~5 mg/kg 投与方法： p.o. (参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	99 mg/mL (198.15 mM) warming
	Ethanol	43 mg/mL warmed (86.06 mM)
	Water	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O 混合させたのち直ちに使用することを推奨します。	7.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Osimertinib (AZD9291) SDFをダウンロードする

分子量	499.61
化学式	C₂₈ H₃₃ N₇ O₂
CAS No.	1421373-65-0
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02841579	Completed	Drug: Osimertinib	Non-Small Cell Lung Cancer	MedSIR\|AstraZeneca	August 2016	Phase 2
NCT02771314	Active not recruiting	Drug: AZD9291	Non Small Cell Lung Cancer	Hellenic Oncology Research Group	August 2 2016	Phase 2
NCT02511106	Active not recruiting	Drug: AZD9291 80 mg/40 mg\|Drug: Placebo AZD9291 80 mg/40 mg	Stage IB-IIIA Non-small Cell Lung Carcinoma	AstraZeneca	October 21 2015	Phase 3
NCT02529995	Completed	Drug: AZD9291 40 mg\|Drug: AZD9291 80 mg	Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive	AstraZeneca	August 24 2015	Phase 1
NCT02491944	Completed	Drug: AZD9291\|Drug: [14C]AZD9291	Oncology	AstraZeneca	July 2015	Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?
回答：
Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFRシグナル伝達経路

相関EGFR製品

Erlotinib

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B)

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Lapatinib

Lapatinib (GSK572016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

研究分野別

製品類型

Osimertinib (AZD9291)

文献中Selleckの製品使用例(205)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Osimertinib (AZD9291) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技術サポート

よくある質問（FAQ）

EGFRシグナル伝達経路

相関EGFR製品